Medicure Inc. (CVE:MPH – Get Free Report)’s stock price crossed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of C$1.21 and traded as low as C$1.14. Medicure shares last traded at C$1.25, with a volume of 766 shares.
Medicure Price Performance
The company has a current ratio of 2.03, a quick ratio of 1.29 and a debt-to-equity ratio of 4.65. The firm’s 50-day moving average price is C$1.21 and its 200-day moving average price is C$1.17. The stock has a market capitalization of C$13.05 million, a PE ratio of -3.79 and a beta of 1.02.
Medicure Company Profile
Medicure Inc, a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications.
Read More
- Five stocks we like better than Medicure
- Do not delete, read immediately
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Your “birthright claim” just got activated
- Wall Street Stockpicker Names #1 Stock of 2026
- Turn your “dead money” into $306+ monthly (starting this month)
Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.
